Oxidative Stress and Heart and Artery Disease in People With Rheumatoid Arthritis
Looks at oxidative stress markers and artery health in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis
Key facts
- Where
- Santa Cruz de Tenerife, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults under 70 with rheumatoid arthritis who take a disease-modifying antirheumatic drug. It studies oxidative stress markers and heart and blood vessel risk.
- Age
- 18 years or older and younger than 70 years
- Sex
- Men and women (not pregnant or breastfeeding)
- Disease stage
- Rheumatoid arthritis. Functional class IV (complete or substantial disability, bed or wheelchair bound) cannot join.
- Earlier treatment
- Must be treated with any disease-modifying antirheumatic drug, including biologic therapies. If taking oral corticosteroids, prednisone 10 mg or less, stable for at least one month.
Main reasons for not taking part
- Another autoimmune rheumatic disease or other inflammatory joint disease
- Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active kidney disease
- Severe uncontrolled heart, nerve, lung, kidney, liver, hormone (including diabetes) or digestive disease
- Body weight greater than 150 kg (331 lb)
- Alcoholism or drug misuse within six months before screening
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario de CanariasSanta Cruz de Tenerife, SpainContact: Ivan Ferraz, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of La Laguna
- Trial code
- NCT07760662
- Record updated
- 12 August 2026
- Original description
The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis.Read full original descriptionShow less
Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis
The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis.
This cross-sectional study will include patients with RA. The primary objective is to evaluate the association between selected oxidative stress biomarkers-serum malondialdehyde levels, superoxide dismutase, and glutathione peroxidase-and the presence of subclinical atherosclerosis and carotid arterial stiffness in patients with RA. We will subsequently assess whether these molecules are related to cardiovascular disease determinants, including inflammatory dyslipidemia, insulin resistance, and beta-cell dysfunction, which may occur in this condition. This study will further explore the relationship between oxidative stress and cardiovascular disease in RA.
Inclusion: Men or women who are not pregnant or breastfeeding; Age 18 years or older and younger than 70 years; Treatment with any disease-modifying antirheumatic drug, including biologic therapies; For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion; Ability and willingness to provide written informed consent.
Exclusion: Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile; History of alcoholism, drug abuse, or substance misuse within six months before the screening visit; Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion; History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease; Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active renal disease; Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care; Pregnancy or breastfeeding; Body weight greater than 150 kg; Statin use will not be an exclusion criterion.